financetom
Business
financetom
/
Business
/
Update: Jabil Shares Fall After Reporting Fiscal Q3 Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Jabil Shares Fall After Reporting Fiscal Q3 Results
Jun 20, 2024 10:48 AM

01:24 PM EDT, 06/20/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and first paragraph.)

Jabil's ( JBL ) shares were down 8.5% in recent Thursday trading after the company reported fiscal Q3 core earnings of $1.89 per diluted share, down from $1.99 a year earlier.

Analysts polled by Capital IQ expected $1.85.

Net revenue for the quarter ended May 31 was $6.77 billion, down from $8.48 billion a year earlier.

Analysts surveyed by Capital IQ expected $6.53 billion.

The company said it expects fiscal Q4 core earnings of $2.03 to $2.43 per diluted share and net revenue of $6.3 billion to $6.9 billion. Analysts surveyed by Capital IQ expect $2.21 normalized earnings and revenue of $6.81 billion.

For full-year 2024, Jabil ( JBL ) maintained its outlook of core earnings of $8.40 per diluted share on net revenue of $28.50 billion. Analysts polled by Capital IQ expect $8.36 normalized earnings on revenue of $28.50 billion.

Price: 115.46, Change: -10.77, Percent Change: -8.53

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Midday Decliners
Top Midday Decliners
Apr 4, 2024
01:54 PM EDT, 04/04/2024 (MT Newswires) -- eFFECTOR Therapeutics ( EFTR ) Chief Executive Officer Steve Worland said there is no obvious path forward to continue developing tomivosertib in frontline NSCLC based on the data currently available after disclosing topline results for the phase 2 trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer. The stock plummeted 81%...
Hedge funds rally in Q1, powered by gains in equities
Hedge funds rally in Q1, powered by gains in equities
Apr 4, 2024
By Carolina Mandl NEW YORK, April 3 (Reuters) - Hedge funds capped the first quarter with gains across different strategies, as a rally in stocks, some commodities and the dollar helped the industry weather a less shiny period for bonds, investors said. Fundamental equities long/short hedge funds were up 6.28% in the first quarter, while systematic long/short funds posted gains...
Market Chatter: Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period
Market Chatter: Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period
Apr 4, 2024
01:51 PM EDT, 04/04/2024 (MT Newswires) -- Pfizer ( PFE ) , Baxter International ( BAX ) , Thermo Fisher Scientific ( TMO ) and around 200 other companies were warned by the US Federal Trade Commission that their merger deals could still be challenged even after the 30-day antitrust review period, Bloomberg reported Thursday. The FTC sent at least...
Goldman, Morgan Stanley must face investors' lawsuit over Archegos collapse
Goldman, Morgan Stanley must face investors' lawsuit over Archegos collapse
Apr 4, 2024
NEW YORK, April 4 (Reuters) - A New York state appeals court said former ViacomCBS investors may sue Goldman Sachs ( GS ) , Morgan Stanley ( MS ) and other banks that underwrote two stock offerings for the media company, upholding a ruling that banks fear could upend capital markets. Thursday's decision by the Appellate Division in Manhattan came...
Copyright 2023-2026 - www.financetom.com All Rights Reserved